Description
This is an invited seminar talk for the WeX seminar at Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London. The talk covered the work of our team characterising the impact of ALS/FTD-linked K181E TDP-43 and the identification of new chaperone activator for neurodegenerative disease treatment.| Period | 10 Jun 2025 |
|---|---|
| Held at | King's College London |
| Degree of Recognition | Regional |
Related content
-
Projects
-
MRC IAA: Drug Screening for Chaperone Response Activation for Neurodegenerative Disorders
Project: Other project (funded) › Restricted grant
-
Publications
-
Familial ALS/FTD-associated RNA-Binding deficient TDP-43 mutants cause neuronal and synaptic transcript dysregulation in vitro
Research output: Contribution to journal › Article › peer-review
-
Identification of novel small molecule chaperone activators for neurodegenerative disease treatment
Research output: Contribution to journal › Article › peer-review